AN1 0.00% 0.8¢ anagenics limited

Just adding onto Tsubas statement, here is a back of the...

  1. 3,152 Posts.
    lightbulb Created with Sketch. 335
    Just adding onto Tsubas statement, here is a back of the envelope calculation on potential.

    We have been told that there are 30000 (at last count) loyal Evolis/Lexilis customers in Japan.
    So that has been accomplished and presumably is growing.
    Out of an eligible population as above of some 60 million that is not exactly a heck of a lot.
    China being nearly 11 times the size of Japan to have the same market penetration would need 330000 loyal customers and the United States 75000.

    That all adds up 435,000 loyal customers as an ongoing base buying 4 products a year at about 20.00 (?) a pop.

    34,800,000 per annum

    based solely on an established Japanese uptake and extrapolated over the US and China, Evolis/Lexilis only, not including Australia or website global, Fillerina.

    There may not be an explosion but there certainly looks like expansion is on its way.

    Im going to stick my neck out and make a cashflow positive call for the 1st quarter of 2019.
    The addition of Bloomingdales and the proceeds from an even subdued Million dollar day in Japan should poke things along IMHO.
    Last edited by Pharmargeddon: 05/06/18
 
watchlist Created with Sketch. Add AN1 (ASX) to my watchlist
(20min delay)
Last
0.8¢
Change
0.000(0.00%)
Mkt cap ! $3.690M
Open High Low Value Volume
0.8¢ 0.8¢ 0.8¢ $336 42K

Buyers (Bids)

No. Vol. Price($)
3 1457234 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 340000 1
View Market Depth
Last trade - 14.19pm 12/07/2024 (20 minute delay) ?
AN1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.